# US 2026/0091025 A1 · Biomolecules involved in alzheimer's disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0091025 A1
- Document ID: US20260091025A1
- Status: Published application
- Kind: A1
- Application number: 19/284,132
- Filed: 2025-07-29
- Published: 2026-04-02
- Earliest claimed: 2015-05-28
- Assignees: Electrophoretics Limited
- Applicants: Electrophoretics Limited
- Inventors: Ian Hugo PIKE; Malcolm Andrew WARD; Claire Louise RUSSELL; Vikram MITRA
- Web page: https://patentgrep.com/patent/US20260091025A1

## CPC

- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K 31/13: Amines {(A61K31/04 takes precedence)}
- A61K 31/445: Non condensed piperidines, e.g. piperocaine
- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K 31/57: substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C07K 14/4711: {Alzheimer's disease; Amyloid plaque core protein}
- C12N 9/16: acting on ester bonds (3.1)
- G01N 33/6896: {Neurological disorders, e.g. Alzheimer's disease}
- G01N 2800/2821: Alzheimer
- G01N 2800/50: Determining the risk of developing a disease
- G01N 2800/56: Staging of a disease; Further complications associated with the disease
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The invention relates to panels of biomarkers including proteins phosphatase 1 regulatory subunit 14A and/or 2′,3′-cyclic-nucleotide 3′-phosphodiesterase and/or phosphorylated tau or fragments thereof and methods using thereof for diagnosing, staging, treating and assessing the response of a treatment for a neurocognitive disorder characterised by tau toxicity, in particular for Alzheimer's disease. The present invention shows that the biomarkers disclosed herein are elevated in the brain of subjects with an advanced stage of a neurocognitive disorder (Braak stage V/VI) and/or are regulated in the CSF of AD subjects in comparison to cognitively affected non-AD controls; and/or regulated in response to two casein kinase 1 delta inhibitors.

## Claims

### Claim at position 1

1-36. (canceled)

### Claim 37

A panel of biomarkers comprising tau or one or more fragments thereof, wherein tau:
i) comprises or has the amino acid sequence of SEQ ID NO:29, and
ii) comprises one or more, optionally two or more, phosphorylated amino acids selected from T39, S46, T50, T52, T56, S61, T63, S64, S68, T69, S113, T181, S184, S185, S191, S195, S198, S199, S202, S205, S208, S210, T212, S214, T217, T231, S235, S237, S238, S258, S262, S285, S289, S356, Y394, S396, S400, T403, S404, S409, S412, S413, T414/S416 or S422;
wherein when the phosphorylated amino acid on tau is T181, the panel comprises tau or one or more fragments thereof having at least one more phosphorylated amino acid.

### Claim 38 (depends on 37)

The panel of claim 37, wherein tau or one or more fragments thereof comprises:
phosphorylated amino acids S61, S64, T181, S184, S202, S205, T231 and/or S235;
phosphorylated amino acids selected from S61, S64, S199, S205, and S396;
phosphorylated amino acid S61;
phosphorylated amino acid S64;
phosphorylated amino acid S199;
phosphorylated amino acid S205;
phosphorylated amino acid S396;
phosphorylated amino acids S61 and S64;
phosphorylated amino acids S61 and S199;
phosphorylated amino acids S61 and S205;
phosphorylated amino acids S61 and S396;
phosphorylated amino acids S64 and S199;
phosphorylated amino acids S64 and S205;
phosphorylated amino acids S64 and S396;
phosphorylated amino acids S199 and S205;
phosphorylated amino acids S199 and S396;
phosphorylated amino acids S205 and S396;
phosphorylated amino acids S61, S64 and S199;
phosphorylated amino acids S61, S64 and S205;
phosphorylated amino acids S61, S64 and S396;
phosphorylated amino acids S61, S199 and S205;
phosphorylated amino acids S61, S199 and S396;
phosphorylated amino acids S61, S205 and S396;
phosphorylated amino acids S64, S199 and S205;
phosphorylated amino acids S64, S199 and S396;
phosphorylated amino acids S64, S205 and S396;
phosphorylated amino acids S199, S205 and S396;
phosphorylated amino acids S61, S64, S199 and S205;
phosphorylated amino acids S61, S64, S199 and S396;
phosphorylated amino acids S61, S199, S205 and S396; or
phosphorylated amino acids S61, S64, S199, S205, and S396.

### Claim 39

A panel of biomarkers comprising a) at least one biomarker selected from Table 5, Table 6, Table 7, Table 8, or Table 9; and b) at least one biomarker selected from tau or one or more fragments thereof, wherein tau:
i) comprises or has the amino acid sequence of SEQ ID NO:29, and
ii) comprises one or more, optionally two or more phosphorylated amino acids selected from T39, S46, T50, T52, T56, S61, T63, S64, S68, T69, S113, T181, S184, S185, S191, S195, S198, S199, S202, S205, S208, S210, T212, S214, T217, T231, S235, S237, S238, S258, S262, S285, S289, S356, Y394, S396, S400, T403, S404, S409, S412, S413, T414/S416 or S422;
wherein when the phosphorylated amino acid on tau is T181, the panel comprises tau or one or more fragments thereof having at least one more phosphorylated amino acid.

### Claim 40 (depends on 39)

A method for diagnosing a neurocognitive disorder in a subject, the method comprising:
a) assaying a sample obtained from said subject for the biomarkers of the panel of claim 39;
b) measuring in said sample a concentration or an amount of each of the biomarkers of said panel; and
c) determining whether that subject has a neurocognitive disorder by comparing said concentration or amount of each of the biomarkers of the panel in said sample with reference concentrations or amounts of said biomarkers.

### Claim 41 (depends on 39)

A method for staging a neurocognitive disorder in a subject, the method comprising:
a) assaying a sample obtained from said subject for the biomarkers of the panel of claim 39;
b) measuring in said sample a concentration or an amount of each of the biomarkers of said panel; and
c) determining the stage of the neurocognitive disorder in said subject by comparing said concentration or amount of each of the biomarkers of the panel in said sample with reference concentrations or amounts of said biomarkers.

### Claim 42 (depends on 39)

A method for assessing in a subject the likelihood of developing a neurocognitive disorder, the method comprising:
a) assaying a sample obtained from said subject for the biomarkers of the panel of claim 39;
b) measuring in said sample a concentration or an amount of each of the biomarkers of said panel; and
c) determining whether that subject is likely to develop a neurocognitive disorder by comparing said concentration or amount of each of the biomarkers of the biomarker panel in said sample with reference concentrations or amounts of said biomarkers.

### Claim 43 (depends on 39)

A method for treating a neurocognitive disorder in a subject, the method comprising:
a) assaying a sample obtained from said subject for the biomarkers of the panel of claim 39;
b) measuring in said sample a concentration or an amount of each of the biomarkers of said panel;
c) determining whether that subject has a neurocognitive disorder by comparing said concentration or amount of each of the biomarkers in said sample with reference concentrations or amounts of said biomarkers; and
d) administering to said subject a drug for treating the neurocognitive disorder.

### Claim 44 (depends on 39)

A method for assessing the response to a drug for treating a neurocognitive disorder in a subject, wherein the subject has been treated or is being treated with said drug, the method comprising:
a) assaying a sample obtained from a subject for the biomarkers of the panel of claim 39;
b) measuring in said sample a concentration or an amount of each of the biomarkers of said panel; and
c) determining whether that subject has responded or is responding to said drug by comparing said concentration or amount of each of the biomarkers in said sample with reference concentrations or amounts of said biomarkers.

### Claim 45 (depends on 40)

The method according to claim 40, wherein the sample comprises cerebrospinal fluid (CSF), blood, plasma, serum, saliva, urine, tissue, or a combination thereof.

### Claim 46 (depends on 40)

The method according to claim 40, wherein the sample is CSF or blood.

### Claim 47 (depends on 40)

The method according to claim 40, wherein the subject is a human subject.

### Claim 48 (depends on 37)

A kit comprising reagents for assaying and/or measuring in a sample the biomarkers of the panel of claim 37.

### Claim 49 (depends on 48)

The kit according to claim 48, wherein the reagents comprise one or more binding agents which specifically bind to the biomarkers of the panels.

### Claim 50 (depends on 49)

The kit according to claim 49, wherein the one or more binding agents are primary antibodies, wherein each primary antibody specifically binds to:
i) a different biomarker of the panel, and/or
ii) one or more phosphorylated amino acids of tau comprising or having the amino acid sequence of SEQ ID NO: 29, or fragments thereof.

### Claim 51 (depends on 48)

The kit according to claim 48, wherein said sample is selected from the group of cerebrospinal fluid (CSF), blood, plasma, serum, saliva, urine, tissue, or a combination thereof.
